Follow-up of patients treated by erlotinib (Tarceval) for a non at small cells lung cancer by PET-F.D.G.: preliminary results

This study is in the frame of the evaluation of targeted therapies. Its principal objective is to provide information on the tumor metabolism evolution by PET-F.D.G. for patients treated for non at small cells bronchi carcinomas by erlotinib (Tarceval), an inhibitor of tyrosine kinase targeting the receptor to epidermal growth factor (E.G.F.). The secondary objectives are to evaluate at term, the interest of the PET-F.D.G. in the identification of responder patients and the early evaluation of the therapy response. (N.C.)